Shots: The EC has approved Byooviz (biosimilar, ranibizumab) in the EU for the treatment of Ophthalmic disease Lucentis is used to treat ophthalmic disease & macular degeneration. Byooviz marks the […]readmore
Shots: The approval is based on results from four clinical trials, including three P-III trials and one P-II trial, that demonstrated significant improvements in both the signs and symptoms of […]readmore
Shots: Henlius to receive upfront, regulatory, and commercial milestone payments of ~$43M, eligible to receive $30M for every $1B above the first $600M of the cumulative net sales along with […]readmore
Shots: Alnylam & Regeneron to co-discover RNAi therapies for eye and CNS diseases. Alnylam to receive $400M upfront, $400M equity at a price of $90/share, $200M as milestones and royalties […]readmore
Shots: The agreement involves Astellas to pay an upfront payment of £85Mn to Quethera’s shareholder’s Quethera uses recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal […]readmore
Copyright © 2020 Digiqole. All Right Reserved.